Authors
Anna Kozlowska, Yan Zhang, Jacqueline Fritz, Steven Wang, Rebecca Codde, Elvira Argus, Samad Ibitokou, Vanitra Richardson, Sumiti Jain, Maximilian Richter, Deepak Patil, Yening Tan, Min Tong, Lu Yao, Majid Ghoddusi, Eric Ostertag, Julia Coronella, Devon Shedlock
Publication date
2020/11/1
Source
Journal for ImmunoTherapy of Cancer
Volume
8
Issue
Suppl 3
Publisher
BMJ Specialist Journals
Description
Background
MUC1 is a highly glycosylated protein that is expressed at the apical border of mucosal epithelium where it plays a protective role. MUC1 is comprised of an N-terminal subunit (MUC1N) tethered to a C-terminal subunit (MUC1C), forming a stable complex on the cell surface. A proteolytic ‘stump’ of MUC1C that may be aberrantly glycosylated is over-represented in cancer, making it an attractive therapeutic target. Here we report generation of allogeneic MUC1C-specific CAR T cells, P-MUC1C-ALLO1, that are designed to leverage the learnings of our P-BCMA-ALLO1 program. P-MUC1C-ALLO1 targets a MUC1C epitope and has the potential for efficacy against a wide range of solid tumors, without targeting normal epithelial cells.
Methods mRNA-generated MUC1C CAR-T cells were evaluated for specificity and function by degranulation assay against various solid tumor and normal cells and cell lines …
Total citations
2023202421